Curium
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · France · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
63 Ave Des Champs-elysées, Paris, Ile-de...Phone Number
+33 153577331Website
www.curiumpharma.comRevenue
$675.1 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
7
7
1
2
2
2
About Curium
Curium, headquartered in Paris, France, is a company that develops, manufactures, and distributes radiopharmaceutical products, including generators, cold kits, hot products, and auxiliary products used in the diagnosis and treatments.Explore more
Curium Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Curium has new funding data
Product Launch: Get notified when Curium launches new products
Congratulate Masked Content for being promoted to Masked Content at Curium
Curium, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Curium is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Curium recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Curium had a recent Job posting/layoffs
Check if Curium has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Curium as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Curium is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curium is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curium.
Curium financials insights
Gather financial insights about Curium, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$265M
2022
Debt
$335M
Curium Tech Stack
A closer look at the technologies used by Curium
See more technologies
Most Recent Scoops
Open Position
Person-Based
Award
Open Position
Open Position
Open Position
Curium News & Media
CVC Credit continues support for Curium through its Capital Solutions strategy
CVC Credit is pleased to announce that it has extended its relationship with Curium, a leading provider of nuclear medicine, through the provision of debt facilities and equity to support the recent refinancing of the business. The transaction saw CVC Credit’s existing investments repaid and CVC Credit reinvest to continue to support Curium's impressive ongoing growth story.Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Curium, a world leading nuclear medicine company dedicated to using cutting-edge technology and innovative science to personalize diagnoses and treatments for patients with cancer, today announced the first dosimetry and pharmacokinetics (PK) data from a substudy of the ongoing pivotal Phase 3 ECLIPSE clinical trial (NCT05204927).Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Curium Shanghai Pharmaceuticals Co., Ltd. (科锐霖（上海）医药有限公司), has had its Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), accepted by the Centre for Drug Evaluation (CDE) and it is now under review.Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that patients in Poland received the first doses of PYLCLARI® (INN: Piflufolastat (18F) also known as 18F-DCFPyL).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curium
Sign Up For FreeTo access detailed company insights
Curium, headquartered in Paris, France, is a company that develops, manufactures, and distributes radiopharmaceutical products, including generators, cold kits, hot products, and auxiliary products used in the diagnosis and treatments.... Read More
